Shares of Chiasma Inc. (NASDAQ:CHMA) have received an average broker rating score of 3.00 (Hold) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold recommendation. Chiasma’s rating score has declined by 20% from 90 days ago as a result of a number of analysts’ ratings changes.

Brokerages have set a 1 year consensus price target of $4.75 for the company and are expecting that the company will post ($0.73) EPS for the current quarter, according to Zacks. Zacks has also given Chiasma an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its stake in Chiasma by 33.7% in the first quarter. Goldman Sachs Group Inc. now owns 17,407 shares of the company’s stock valued at $159,000 after buying an additional 4,392 shares during the last quarter. Opaleye Management Inc. bought a new stake in Chiasma during the first quarter valued at $183,000. A.R.T. Advisors LLC acquired a new stake in shares of Chiasma during the second quarter valued at approximately $441,000. Athena Capital Advisors LLC acquired a new stake in shares of Chiasma during the first quarter valued at approximately $496,000. Finally, Geode Capital Management LLC boosted its stake in shares of Chiasma by 19.4% in the first quarter. Geode Capital Management LLC now owns 55,693 shares of the company’s stock valued at $510,000 after buying an additional 9,038 shares in the last quarter. Hedge funds and other institutional investors own 58.76% of the company’s stock.

Chiasma (NASDAQ:CHMA) traded up 2.72% during midday trading on Monday, hitting $2.64. 12,571 shares of the stock were exchanged. The company has a 50 day moving average price of $2.69 and a 200 day moving average price of $4.70. Chiasma has a one year low of $2.40 and a one year high of $28.46. The firm’s market capitalization is $64.30 million.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.47. Equities analysts anticipate that Chiasma will post ($3.14) EPS for the current year.

About Chiasma

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

5 Day Chart for NASDAQ:CHMA

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.